Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart Failure (RAFT)
Source: View publication →
The RAFT trial demonstrated that adding cardiac resynchronization therapy (CRT) to an implantable cardioverter-defibrillator (ICD) reduces all-cause mortality and heart failure hospitalizations in patients with mild-to-moderate heart failure, left ventricular dysfunction, and a wide QRS complex.
Key Findings
Study Design
Study Limitations
Clinical Significance
The RAFT trial established the standard of care for using CRT-D in patients with NYHA class II or III symptoms who have a wide QRS complex and reduced left ventricular ejection fraction, providing evidence for mortality reduction in this less symptomatic population compared to ICD therapy alone.
Historical Context
Prior to RAFT, CRT was primarily indicated for patients with severe (NYHA class III/IV) heart failure. RAFT expanded the evidence base to include the more ambulatory, mildly symptomatic population, influencing international guidelines and solidifying the role of resynchronization therapy in earlier stages of heart failure.
Guided Discussion
High-yield insights from every perspective
What is the physiologic rationale for using a biventricular pacemaker (CRT) in a patient with a wide QRS complex and heart failure, and how does it improve cardiac output?
Key Response
A wide QRS complex, particularly with Left Bundle Branch Block (LBBB), indicates electrical dyssynchrony where the left ventricular lateral wall contracts later than the septum. This reduces the efficiency of the pump. CRT provides biventricular pacing to resynchronize the contraction, decreasing functional mitral regurgitation, improving ventricular filling time, and increasing the left ventricular ejection fraction (LVEF) through more coordinated mechanical activity.
Based on the RAFT trial, which specific NYHA classes and QRS thresholds define the population that benefits from CRT-D, and what was the impact on all-cause mortality?
Key Response
The RAFT trial enrolled patients with NYHA Class II or III heart failure, an LVEF of 30% or less, and a QRS duration of 120 ms or more (or a paced QRS of 150 ms or more). Unlike some previous trials that focused primarily on hospitalizations, RAFT demonstrated that adding CRT to an ICD significantly reduced all-cause mortality (hazard ratio 0.75) in addition to reducing heart failure hospitalizations.
How did the RAFT trial's findings regarding QRS morphology and duration influence our understanding of 'non-responders,' and how do these results compare to the MADIT-CRT subgroup analyses?
Key Response
Subgroup analysis in RAFT suggested that the benefit of CRT-D was most pronounced in patients with a QRS duration of 150 ms or greater. Similar to MADIT-CRT, subsequent interpretations of RAFT data emphasized that patients with LBBB morphology derive significantly more benefit than those with non-LBBB patterns (e.g., RBBB or IVCD). This has led to the current practice of prioritizing CRT in patients with LBBB and wider QRS durations to minimize the rate of clinical non-response.
The RAFT trial reported a higher rate of device-related complications in the CRT-D group compared to the ICD-only group. How should this data shape the shared decision-making process for a NYHA Class II patient with borderline QRS duration?
Key Response
Attending-level care requires balancing the 25% relative risk reduction in mortality against the increased risk of peri-procedural complications (14% in CRT-D vs 6.7% in ICD-only at 30 days). For a 'mild' HF patient with a QRS of 120-130ms, the clinician must discuss that while long-term survival is improved, the risk of lead displacement, infection, and procedural failure is significantly higher with the more complex CRT-D system.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
RAFT utilized a time-to-first-event composite endpoint of death or HF hospitalization. From a trial design perspective, how might a recurrent-events analysis (e.g., Andersen-Gill model) have altered the perceived treatment effect compared to the traditional Cox proportional hazards model?
Key Response
Traditional time-to-first-event analyses ignore subsequent heart failure hospitalizations after the initial event, potentially underestimating the total disease burden and the full magnitude of the treatment effect. A recurrent-events model would capture the cumulative reduction in hospitalizations over the 40-month mean follow-up, likely providing a more robust estimate of the therapy's impact on healthcare utilization and chronic disease stability.
Given that the RAFT trial could not be double-blinded due to the nature of the device implantation, what measures were taken to protect the 'hospitalization for heart failure' endpoint from detection bias, and is the mortality benefit sufficient to overcome this potential weakness?
Key Response
The potential for bias in non-blinded trials lies in the subjective decision to hospitalize. RAFT mitigated this by using an independent, blinded adjudication committee for all clinical events. However, the fact that the mortality benefit (an objective, 'hard' endpoint) was statistically significant (p=0.003) serves as a critical internal validation, reassuring editors that the overall study conclusions are not merely artifacts of biased hospitalization decisions.
How did the RAFT trial change the strength of recommendation for CRT in NYHA Class II patients compared to previous iterations of the ACC/AHA/HFSA guidelines?
Key Response
Prior to trials like RAFT and MADIT-CRT, CRT was primarily a Class I recommendation for NYHA Class III/IV. RAFT provided the necessary evidence for 'mild' heart failure (Class II) to be upgraded. Current guidelines (e.g., 2022 AHA/ACC/HFSA) now give a Class 1 recommendation for CRT in patients with LVEF ≤35%, LBBB, and QRS ≥150ms who are in NYHA Class II, III, or ambulatory IV, specifically citing the mortality benefits seen in RAFT.
Clinical Landscape
Noteworthy Related Trials
COMPANION Trial
Tested
Cardiac resynchronization therapy (CRT) or CRT plus an implantable cardioverter-defibrillator (CRT-D)
Population
Patients with NYHA class III or IV heart failure and prolonged QRS interval
Comparator
Optimal pharmacological therapy alone
Endpoint
Composite of death from any cause or first hospitalization
CARE-HF Trial
Tested
Cardiac resynchronization therapy (CRT)
Population
Patients with NYHA class III or IV heart failure, left ventricular systolic dysfunction, and cardiac dyssynchrony
Comparator
Optimal medical therapy
Endpoint
Composite of death from any cause or an unplanned hospitalization for major cardiovascular events
MADIT-CRT Trial
Tested
Cardiac resynchronization therapy with an implantable cardioverter-defibrillator (CRT-D)
Population
Patients with asymptomatic or mildly symptomatic (NYHA class I or II) heart failure, reduced LVEF, and prolonged QRS
Comparator
Implantable cardioverter-defibrillator (ICD) alone
Endpoint
Death from any cause or a nonfatal heart-failure event
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis